Combined Aerobic-Resistance Training and Taurine Supplementation Reduce Asprosin and Elevate Spexin in Men with Obesity: A 12-Week Supplement-Blinded, Randomized Controlled Trial.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

Asprosin, a white adipose tissue-derived glucogenic adipokine, and spexin, a satiety-promoting neuropeptide, are dysregulated in obesity, yet their collective modulation by structured exercise and nutritional supplementation remains poorly characterized.

This trial investigated the effects of 12 weeks of combined aerobic-resistance training, with and without taurine supplementation, on plasma asprosin, spexin, and body composition in obese men.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, men only.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Copper (Supplement), so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Copper (Supplement) could be set against what happens without it.

Plasma asprosin and spexin were quantified by ELISA; body fat percentage (BFP) was assessed by bioelectrical impedance analysis.

Two-way repeated-measures ANOVA with Bonferroni post hoc correction and Cohen's d effect size estimation were applied throughout.

What Was Measured

The subject headings attached to it are Obesity, Dietary Supplements, Peptide Hormones, Taurine, Resistance Training, Fibrillin-1 and Exercise.

The authors tagged it with the keywords adiponectin, energy metabolism, gluconeogenesis, hypothalamus, insulin resistance and metabolic syndrome.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Copper (Supplement).

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2026 (Nutrients), a journal based in Switzerland.

More context: the Copper (Supplement) compound page, all human trials.